 |

|
 |
 |
 |
 |
 |
 |
3SBio
Fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China
IPO in May 2015 (HKSE: 1530)
|
AADI Bioscience
Clinical stage biopharmaceutical company developing a nanoparticle albumin-bound mTOR inhibitor based on sirolimus or rapamycin, also known as nab-rapamycin |
Alpine Immune Sciences
Biotech company developing innovative treatments for patients suffering from cancer and autoimmune/inflammatory diseases |
Apexigen
Clinical-stage biopharmaceutical company focusing on the discovery and development of innovative antibody-based therapeutics for the treatment of cancer with a focus on immuno-oncology |

|
 |
 |
 |
 |
 |
 |
 |
Arcus Biosciences
Clinical-stage biotechnology company focused on the discovery and development of innovative cancer immunotherapies
IPO in March 2018 (NASDAQ:RCUS) |
Ariagen
Biotech company founded by Decheng Capital to develop a novel class of small molecules as cancer immunotherapies |
ARMO Biosciences
Late-stage immuno-oncology company that is developing a pipeline of novel, proprietary products that activate the immune system of cancer patients to recognize and eradicate tumors
Acquired by Eli Lilly in May 2018 |
Checkmate Pharmaceuticals
Clinical stage biopharma company that is leveraging its expertise in the field of CpG oligonucleotides to discover and develop immunotherapies designed to increase the efficacy of existing immunotherapies |
 |

|
 |

|
 |
 |
 |
 |
EpimAb Biotherapeutics
Biopharmaceutical company dedicated to generating novel bi-specific antibody therapeutics based on its proprietary FIT-Ig (Fabs-In-Tandem) platform |
Hummingbird Bioscience
Biotech company, with facilities in Singapore and Silicon Valley, focused on applying advances in systems biology to rapidly develop antibodies into successful cancer therapeutics
|
IMPACT Therapeutics
Clinical stage biopharmaceutical company focusing on discovery and development of best-in-class anti-cancer drugs targeting a poly (ADP-ribose) polymerase (PARP) |
Terns Pharmaceuticals
Clinical stage biopharma company based in Shanghai and Silicon Valley developing oral, small molecule drugs for nonalcoholic steatohepatitis (NASH), a liver disease |
 |
|
|
|
 |
|
|
|
VelosBio
Biopharma company focused on developing an antibody-drug conjugate of cirmtuzumab, a ROR1 antibody |
|
|
|